Skip to main content

Assessment of ARIA Sufficiency: Rinvoq (upadacitinib)

    Basic Details
    Approval Date
    Friday, January 14, 2022
    Original Posting Date
    Health Outcome(s)
    adverse pregnancy and fetal outcomes
    major adverse cardiovascular events
    malignancy
    thrombosis